SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study

1. voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ; the age at the time of signing the informed consent form is 18-75 years old ( including both ends ), both men and women can.

   The ECOG score was 0 or 1.

2. Participants with locally advanced or metastatic non-squamous non-small cell lung cancer confirmed by histology or cytology.
3. Adequate bone marrow and organ function.

Exclusion Criteria:

1. Anti-tumor therapy such as chemotherapy, biological therapy, targeted therapy, immunotherapy or other unlisted clinical research drugs or treatments were received within 4 weeks before the first medication.
2. Untreated or active central nervous system tumor metastasis
3. Imaging showed that the tumor invaded important organs or tumor surrounding / invasion of large blood vessels or there was obvious necrosis / cavity, which was judged by the researchers to have a risk of bleeding.
4. History of interstitial pneumonia or participants who cannot rule out interstitial pneumonia ; or other moderate to severe lung diseases ; or received previous pneumonectomy surgery
5. Participants with severe cardiovascular and cerebrovascular diseases
6. Have a history of severe bleeding tendency or coagulation dysfunction ; bleeding symptoms with significant clinical significance occurred within 3 months before the first medication.
7. Arterial and venous thrombosis events occurred within 6 months before the first administration ;
8. HIV test positive
9. Participants with active hepatitis B or C
10. Severe infection occurred within 4 weeks before the first administration
11. Allergy to any component of the treatment regimen